Business Context and Reporting Period
This Form 8-K filing by Big Rock Partners Acquisition Corp. (not NRX Pharmaceuticals, Inc.) covers events occurring on August 21, 2019. The registrant is a Special Purpose Acquisition Company (SPAC) incorporated in Delaware, trading on the NASDAQ under symbols BRPAU, BRPA, BRPAR, and BRPAW. The report details the results of a special meeting of stockholders held to address the timeline for consummating an initial business combination.
Key Financial Metrics and Liquidity
The filing does not provide comprehensive financial statements, revenue, or profit data. Key liquidity and capital structure updates include:
- Trust Account Deposit: Following the shareholder vote, the Company deposited $78,666.80 into its trust account. This represents $0.02 per public share that was not converted.
- Share Conversions: Holders of 846,888 shares exercised their right to convert shares into cash during the meeting.
- Extension Funding: The deposit covers the first monthly extension period. The Company retains the option to deposit additional funds for up to two more monthly extensions.
Material Changes and Corporate Actions
Two material proposals were approved by stockholders at the special meeting:
- Extension of Business Combination Deadline: The Company amended its certificate of incorporation to extend the deadline to consummate a business combination to November 22, 2019.
- Voting Results: 4,935,105 votes For; 300,001 votes Against; 0 Abstain.
- Early Winding Up Proposal: Stockholders approved a proposal to adopt and approve the early winding up of the Company and redemption of 100% of outstanding public shares if the Board determines prior to the extended date that a business combination cannot be consummated.
- Voting Results: 5,234,305 votes For; 801 votes Against; 0 Abstain.
Outlook, Risks, and Management Commentary
Management has secured a new deadline of November 22, 2019, to complete an initial business combination. The filing indicates a contingency plan where the Company may deposit additional funds into the trust account for up to two additional monthly extension periods if necessary. The primary risk remains the Company's ability to consummate a business combination by the extended date; failure to do so will trigger the approved early winding up and full redemption of public shares.
Investor Verification Checklist
- Verify the exact number of public shares outstanding post-conversion to confirm the total trust account balance.
- Confirm the specific terms and conditions for the potential additional monthly extension deposits.
- Monitor subsequent filings for any updates on potential business combination targets before the November 22, 2019 deadline.
- Note that the filing metadata referenced "NRX Pharmaceuticals, Inc." is incorrect; the registrant is Big Rock Partners Acquisition Corp.